PT  - JOURNAL ARTICLE
AU  - KATSUJI KOKAWA
AU  - RYUICHIRO NISHIMURA
AU  - TUNEO FUJII
AU  - NAOHIKO UMESAKI
TI  - Neoadjuvant Chemotherapy with Irinotecan and Mitomycin-C for Locally Advanced Squamous Cell Carcinoma of the Uterine Cervix
DP  - 2007 Jul 01
TA  - Anticancer Research
PG  - 2721--2727
VI  - 27
IP  - 4C
4099  - http://ar.iiarjournals.org/content/27/4C/2721.short
4100  - http://ar.iiarjournals.org/content/27/4C/2721.full
SO  - Anticancer Res2007 Jul 01; 27
AB  - Background: The efficacy and toxicity of combined therapy with irinotecan (CPT-11) and mitomycin-C (MMC) in a neoadjuvant setting were evaluated in patients with locally advanced squamous cell carcinoma (SCC) of the uterine cervix. Patients and Methods: Eligibility included patients with previously untreated cervical carcinoma. CPT-11 (100 mg/m2) was administered on days 1, 8 and 15 intravenously (i.v.), while MMC (10 mg/m2 i.v.) was given on day 1. Survival curves were generated using the Kaplan-Meier method. Results: Among 35 eligible patients, 3 showed a complete response and 27 a partial response, with an overall response rate of 85.7%. No patient showed progressive disease. Thirty-three patients were able to undergo radical surgery after neoadjuvant chemotherapy and only 2 patients (stage IIIb) received radiotherapy without the optimal surgery. The median disease-free survival (DFS) period was 42 months (range 5-73). The median overall survival (OAS) period was 44 months (range 17-74). Two-year DFS and OAS rates were 74.3% and 91.4%, respectively. Of the 58 treatment cycles administered, grade 3 or 4 neutropenia and thrombocytopenia were observed in 50% and 9% of the treatment cycles, respectively. Grade 3 or 4 diarrhea was observed in 6%. Conclusion: Neoadjuvant chemotherapy with CPT-11 and MMC can be effective and well-tolerated against locally advanced SCC of the uterine cervix.